Expert Insights and Case Challenges: Sorting Through the Treatment Options for CLL

Friday, September 10, 2021

6:00 pm – 7:30 pm  CDT

Virtual
CME
swoosh
swoosh

OVERVIEW

Join us for this interactive case-based symposium that will provide best practices and clinical pearls for treating patients with chronic lymphocytic leukemia (CLL). Experts will review the supporting clinical trial data for available therapies; considerations for personalizing treatment; and strategies to manage adverse events for patients with CLL in both the frontline and relapsed settings. Additionally, novel agents and combination strategies will be discussed along with how they may fit into the treatment armamentarium.

 

Back Stage Pass Logo

 

 

 

Enhance Your Virtual Experience With Backstage Pass!

Join our 30-minute post-symposium conversation connecting the program speakers and audience in an intimate interactive session where you can address case-based questions, gain valuable insights, and facilitate relationship building. Participation with video encouraged.

 

To access tonight’s event, please click on the link below.

If you are having difficulty accessing the event above, please use this alternative link to join the simulcast by clicking here.

FACULTY

AGENDA

ENHANCE YOUR EXPERIENCE WITH MEDCHALLENGE!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

TARGET AUDIENCE

This activity is for hematologists/oncologists and others involved in the care of patients with CLL. 

GOAL STATEMENT

The overall goals of this initiative are to improve the skills of hematologists/oncologists to personalize treatment and manage side effects in patients with CLL and to improve their knowledge about emerging treatment strategies. 

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Prognostic significance of measurable residual disease (MRD) status at the completion of CLL therapy  [ITEM]Emerging strategies for treating CLL [/LIST] Have greater competence related to [LIST][ITEM]Individualizing therapy for patients CLL   [ITEM]Managing side effects of CLL therapies[/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]

[BOLD]For Physicians[/BOLD] Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.